CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Magstim SuperRapid +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04043312
NCT04043312N/ACompleted

A Randomized Controled Trial of Transcutaneous Magnetic Stimulation of the Stellate Ganglion to Treat Ventricular Tachycardia Storm

University of Pennsylvania·interventional·Posted Aug 2, 2019·Updated Nov 8, 2022

In Brief

A clinical study evaluating Magstim SuperRapid for Ventricular Tachycardia. Completed, enrolled 26 participants across 1 site.

Detailed Summary

Ventricular Tachycardia storm is a medical emergency characterized by three or more episodes of ventricular arrhythmia within 24 hours and associated with a significantly increased mortality and massive health resource utilization. Several therapies are utilized including sympathetic blockade (through deep sedation and beta blockers), antiarrhythmic drugs, implantable cardioverter defibrillator (ICD) reprograming where applicable, and catheter ablation. Despite standard intervention, mortality rates remain high and additional therapeutic options are actively being investigated. The overall objective of this proposal is to investigate whether transcutaneous magnetic stimulation designed to inhibit the left stellate ganglion can be used in this population. This is a single-center, randomized, sham-controlled trial to assess the efficacy of transcutaneous magnetic stimulation of the left stellate ganglion to treat patients with ventricular tachycardia storm.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedAug 2, 2019
Enrollment StartAug 14, 2019
Primary CompletionJun 30, 2021
Study CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.9 years ago

Interventions

Magstim SuperRapiddevice

Transcutaneous magnetic stimulation targeting the left stellate ganglion.

Magstim SuperRapiddevice

Sham transcutaneous magnetic stimulation.